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Traditionally, upstream processing in biologics manufacturing is performed in an aseptic and functionally closed 
manner while downstream processes are open operations designed to maintain a low-bioburden state. 
Consequently, the downstream process components such as skids, column hardware, and chromatography resins 
currently available have been designed for low bioburden rather than aseptic operations. One of the key design 
elements of Integrated Continuous Biomanufacturing (ICB) is the linkage of upstream and downstream operations 
and the capability of the system to run for prolonged durations at ambient temperature. Thus, a critical design 
criterion for ICB is the ability of the system to maintain a bioburden-free state. This study demonstrates the 
development of novel tools and methodologies to address the need for at-scale bioburden-free downstream 
operations for ICB. 
 
Both engineering and operational solutions were identified to achieve bioburden-free integration of a bioreactor 
with a periodic counter-current (PCC) skid. The engineering/operational solutions included the construction of a 
SIPable and functionally- closed manufacturing scale PCC skid, disposable and functionally-closed 
chromatography columns coupled with an innovative strategy to render them bioburden-free, as well as the use 
of tubing welders. To this end, we have successfully demonstrated at-scale operation for integrated capture of 
both a stable (monoclonal antibody) and an unstable molecule (recombinant enzyme) for over 40 days each. 
Samples from different points of the system showed that the operation was bioburden-free for the duration of the 
campaign. Additionally, no indication of time based performance decline was observed for either the mAb or 
enzyme capture step. Overall, our findings demonstrate successful scale-up of a functionally-closed, integrated 
and continuous capture step operated for weeks in a bioburden-free state. Such principles and solutions can be 
further extended to subsequent downstream unit operations, enabling the development of an end-to-end 
biomanufacturing platform. Environmental control requirements for a functionally closed end-to-end cGMP facility 
can potentially result in dramatic reductions for both OPEX and CAPEX.  
 
